Purpose: Some studies have suggested a protective role of statins in Head and Neck Squamous Cell Carcinoma (HNSCC) even though the real contribution of statins to morbidity and survival remains unclear. Study Design: Retrospective case-control Methods: The aim of this review is to retrospectively evaluate the oncological protection and the outcome of the statin intake in a population of patients affected by larynx squamous cell carcinoma that underwent total or partial laryngectomy. We analyzed 109 patients with a focus on the percentage of statin intake. Overall survival (OS) was compared between patients underwent total or partial laryngectomy assuming statin or not. Furthermore, we compare statin intake in cancer patients with a population of non-cancer patients. We analyzed if statin intake could be statistically significant in increasing the overall survival. Results: The Kaplan-Meier survival curves for oncologic population assuming statins was 94,7% and 78% for patients that were not assuming statins. The Cox multivariate regression analysis didn’t identify a statistically significant OS benefit with statin intake Conclusion: Statin intake at the time of diagnosis of squamous cell carcinoma of the larynx has shown an improved OS even though statin consumption didn’t appear as a statistically significant variable probably due to the small number of patients analyzed. Another probable cause is the feedback of a medium delay of about ten years in statin assumption compared to the onset of the tumor and the emerged data of a smaller percentage of people assuming statins from the population analyzed, compared to the national medium.

Objectives: The aim of this study has been to analyze effects on Quality of Life (QoL) of the multilevel surgery for Obstructive Sleep Apnea (OSA). Also, we have compared the impact on QoL of two different treatments for patients with moderate to severe OSA such as CPAP and transoral robotic surgery (TORS). Design: 67 OSA patients who underwent multilevel robotic surgery and 67 OSA patients treated with CPAP were enrolled in a Group 1 and Group 2 respectively. The Glasgow Benefit Inventory (GBI) questionnaire has been administrated to all patients to evaluate the changes in the QoL after the different OSA treatment. Respiratory outcomes pre and post treatment were evaluated and compared. Results: Group 1 showed a GBI total average value of +30.4, whereas the group 2 a value of +33.2 . No statistical difference emerged (p=0.4). General benefit score showed no difference between groups (p = 0.1). Better values of social status benefit (p= 0.0006) emerged in CPAP Group, whereas greater physical status benefit (p=0.04) was showed in TORS Group. Delta-AHI (-23.7 ± 14.3 vs -31.7 ± 15.6; p = 0.001), Delta-ODI (-24.5 ± 9.5 vs. -29.4 ±10.5; p = 0.001) showed better values in CPAP group. Therapeutic success rate of Multilevel TORS Group was 73.1% and 91% in CPAP group (p = 0.01) respectively. Conclusion: Multilevel TORS and CPAP have a positive effect in quality of life of OSA patients. Greater social support has been reported in CPAP group and better physical health status in TORS group.